/C O R R E C T I O N -- Privo Technologies/
3 minute readPublished: Friday, January 23, 2026 at 10:32 pm
Privo Technologies Announces Positive Results for Head and Neck Cancer Treatment
BOSTON, January 23, 2026 – Privo Technologies has announced the successful completion of its Phase 1/2 clinical study of PRV211, an intraoperative chemotherapy patch designed for head and neck cancer patients. The study, which focused on the safety profile of the treatment, demonstrated positive results, marking a significant step forward in the fight against cancer recurrence.
The study involved eight patients and showed an excellent safety profile. There were no treatment-related serious adverse events reported. The only reported side effect was a mild burning sensation during healing. Furthermore, the study found no systemic toxicities or dose-limiting toxicities, and normal wound healing occurred without surgical complications. The patch also showed negligible systemic absorption, confirming its targeted delivery mechanism.
PRV211 is designed to be applied directly to the tumor bed following surgical removal of the tumor. This innovative approach aims to address microscopic cancer cells that may remain in the surgical margins, potentially reducing the risk of cancer recurrence. The patch utilizes nanoengineered technology to deliver localized chemotherapy.
The study enrolled patients with invasive tumors requiring surgical excision, including advanced-stage cases. The targeted approach of PRV211 delivers chemotherapy directly to the surgical site, minimizing exposure to the rest of the body.
This study is part of Privo Technologies' CLN-004 clinical program. The company is also making progress in other areas of the program. Patients will be monitored for efficacy outcomes, including loco-regional recurrence at 12 months post-surgery. A future expansion study is planned to further evaluate PRV211's potential to reduce cancer recurrence.
BNN's Perspective: The results from this study are encouraging, offering a potential new tool in the fight against head and neck cancer. The focus on localized treatment, with its potential to reduce side effects, is a positive development. While further studies are needed to confirm efficacy, this approach could significantly improve patient outcomes and quality of life.
Keywords: Privo Technologies, PRV211, head and neck cancer, chemotherapy, clinical trial, cancer recurrence, intraoperative, nanoengineered, localized therapy, cancer treatment, safety, Phase 1/2 study.